Woburn, Mass. – May 22, 2023 − Aphios Corporation is pleased to announce today that its Founder and CEO, Dr. Trevor P. Castor will chair the roundtable discussion on “Transcytosis-mediated brain delivery of proteins, antibodies, oligonucleotides and small molecules” at HubXchange’s CNS Therapeutics Xchange East Coast 2023, Hilton Boston Woburn Hotel, May 24, 2023.
The CNS Therapeutics Xchange will bring together executives from pharmaceutical and biotechnology companies to address and find solutions for key issues in the development of CNS therapeutics. This meeting will cover novel targets, preclinical research, clinical studies and drug delivery. HubXchange hosts executive meetings that deliver high content, intelligence and connections to the global life sciences community.
The roundtable discussion on transcytosis-mediated brain delivery of proteins antibodies, oligonucleotides, and small molecules will address the following topics:
- Challenges in crossing and transporting proteins, antibodies, oligonucleotides and small molecules across the blood brain barrier (BBB).
- BBB transcellular transport via receptor-mediated transcytosis targeting the transferrin, insulin, low density lipoprotein and other receptors.
- Nanoparticles and their surface modifications are used for brain delivery including liposomes, polymer nanospheres, dendrimers, protein drug conjugates and other biological nanoparticles.
- Other transport systems for crossing the BBB and delivering proteins, antibodies, oligonucleotides and small molecules into the brain include virus-like particles (VLPs) and targeting endothelial cells.
About Aphios Corporation:
Aphios (www.aphios.com) is an emerging growth, green biotechnology company developing enabling technology platforms to improve drug discovery and manufacturing, nanotechnology drug delivery and pathogenic safety. Based on these platforms, Aphios is developing enhanced therapeutics to improve quality-of-life and treat chronic diseases including cancers, infectious diseases such as HIV/AIDS, and central nervous system disorders in an environmentally sustainable manner.